Private Portfolio Partners LLC Purchases 276 Shares of AbbVie Inc. (NYSE:ABBV)

Private Portfolio Partners LLC raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 2.8% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,995 shares of the company’s stock after acquiring an additional 276 shares during the period. Private Portfolio Partners LLC’s holdings in AbbVie were worth $1,126,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. 4Thought Financial Group Inc. bought a new position in AbbVie during the second quarter valued at $25,000. Cowen Prime Advisors LLC bought a new position in shares of AbbVie in the second quarter worth about $34,000. ShoreHaven Wealth Partners LLC grew its holdings in shares of AbbVie by 150.4% in the first quarter. ShoreHaven Wealth Partners LLC now owns 318 shares of the company’s stock worth $35,000 after purchasing an additional 191 shares during the last quarter. KB Financial Partners LLC bought a new position in shares of AbbVie in the first quarter worth about $37,000. Finally, Centerpoint Advisors LLC bought a new position in shares of AbbVie in the second quarter worth about $39,000. Institutional investors and hedge funds own 65.82% of the company’s stock.

In related news, SVP Carrie C. Strom sold 5,057 shares of the stock in a transaction that occurred on Monday, August 23rd. The shares were sold at an average price of $120.00, for a total value of $606,840.00. Following the completion of the transaction, the senior vice president now directly owns 11,595 shares of the company’s stock, valued at approximately $1,391,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.09% of the company’s stock.

Shares of ABBV stock traded up $0.40 during mid-day trading on Tuesday, hitting $106.80. 91,785 shares of the stock traded hands, compared to its average volume of 7,056,760. The stock has a market cap of $188.73 billion, a P/E ratio of 28.68, a P/E/G ratio of 2.01 and a beta of 0.82. The stock’s fifty day moving average is $115.05 and its two-hundred day moving average is $112.81. AbbVie Inc. has a 52-week low of $79.11 and a 52-week high of $121.53. The company has a debt-to-equity ratio of 5.89, a current ratio of 0.91 and a quick ratio of 0.79.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Thursday, July 29th. The company reported $3.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.09 by $0.02. The business had revenue of $13.96 billion during the quarter, compared to analyst estimates of $13.64 billion. AbbVie had a net margin of 12.40% and a return on equity of 154.24%. The company’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.34 earnings per share. As a group, equities analysts forecast that AbbVie Inc. will post 12.64 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 15th. Investors of record on Friday, October 15th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 4.87%. The ex-dividend date is Thursday, October 14th. AbbVie’s payout ratio is currently 49.24%.

ABBV has been the topic of a number of research analyst reports. Mizuho upped their price target on shares of AbbVie from $128.00 to $131.00 and gave the stock a “buy” rating in a report on Monday, August 2nd. Barclays upped their price target on shares of AbbVie from $105.00 to $112.00 and gave the stock an “equal weight” rating in a report on Monday, August 2nd. Daiwa Capital Markets assumed coverage on shares of AbbVie in a report on Friday, July 2nd. They issued an “outperform” rating on the stock. SVB Leerink lowered their price objective on shares of AbbVie from $148.00 to $142.00 and set an “outperform” rating for the company in a research note on Thursday, September 2nd. Finally, Morgan Stanley reaffirmed a “buy” rating and issued a $116.00 price objective on shares of AbbVie in a research note on Friday, August 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $123.47.

About AbbVie

AbbVie, Inc is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions.

Recommended Story: What is required to own or exchange cryptocurrency?

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.